New classification criteria for axial disease in juvenile spondyloarthritis aim to enhance the identification and study of this condition in affected youth, offering a tool for future non-interventional studies and interventional trials. Better understanding of the efficacy of various interventions in the axial domain could help tailor treatment strategies.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Weiss, P. F. et al. Classification criteria for axial disease in youth with juvenile spondyloarthritis. Arthritis Rheumatol. https://doi.org/10.1002/art.42959 (2024).
Flato, B., Aasland, A., Vinje, O. & Forre, O. Outcome and predictive factors in juvenile rheumatoid arthritis and juvenile spondyloarthropathy. J. Rheumatol. 25, 366–375 (1998).
Weiss, P. F. et al. Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry. J. Rheumatol. 39, 2341–2351 (2012).
Selvaag, A. M. et al. Early disease course and predictors of disability in juvenile rheumatoid arthritis and juvenile spondyloarthropathy: a 3 year prospective study. J. Rheumatol. 32, 1122–1130 (2005).
Deodhar, A. et al. Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis. Arthritis Rheumatol. 71, 258–270 (2019).
Baeten, D. et al. Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study. Ann. Rheum. Dis. 77, 1295–1302 (2018).
Hueber, W. et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61, 1693–1700 (2012).
Poddubnyy, D. et al. Axial Involvement in Psoriatic Arthritis cohort (AXIS): the protocol of a joint project of the Assessment of SpondyloArthritis international Society (ASAS) and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). Ther. Adv. Musculoskelet. Dis. 13, 1759720X211057975 (2021).
Weiss, P. F. et al. Data-driven magnetic resonance imaging definitions for active and structural sacroiliac joint lesions in juvenile spondyloarthritis typical of axial disease: a cross-sectional international study. Arthritis Care Res. 75, 1220–1227 (2023).
Weiss, P. F. et al. Radiographs in screening for sacroiliitis in children: what is the value? Arthritis Res. Ther. 20, 141 (2018).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.P. has received research support from AbbVie, Eli Lilly, MSD, Novartis, Pfizer, consulting fees from AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Moonlake, Novartis, Pfizer and UCB, and speaker fees from AbbVie, Canon, DKSH, Eli Lilly, Janssen, MSD, Medscape, Novartis, Peervoice, Pfizer and UCB, and is a member of the Assessment of SpondyloArthritis International Society executive committee and of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis steering committee.
Rights and permissions
About this article
Cite this article
Poddubnyy, D. Defining axial involvement in juvenile SpA. Nat Rev Rheumatol 21, 3–4 (2025). https://doi.org/10.1038/s41584-024-01170-0
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41584-024-01170-0
